Evaro lands €21m Series A to expand embedded NHS-licensed services
Evaro, a Norwich-based digital healthcare platform that provides NHS-licensed, embedded prescription and care services, has raised €21 million (about $25 million) in a Series A funding round as it looks to broaden its clinical offering and scale integrations with consumer brands.
The round was led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The company said the new capital will be used to expand into additional treatment areas including women’s health, men’s health and longevity medicine, as well as to deepen clinical capabilities such as diagnostics and aftercare and to further develop its API-first platform infrastructure.
From brand partnerships to “healthcare-as-a-service”
Evaro positions itself as regulated infrastructure that lets consumer brands and digital platforms offer prescription services without building their own clinical, pharmacy, and compliance stack. The company already works with period-tracking app Clue and sexual wellness retailer Lovehoney, embedding regulated prescription services directly into their customer experiences.
According to the company, integrations can be completed quickly, enabling partners to add a healthcare layer to existing customer journeys. This model aims to make access to care more convenient while creating a new revenue stream for partners and strengthening customer retention through additional services.
CEO: pressure on primary care demands alternatives
Dr Thuria Wenbar, CEO and co-founder of Evaro, framed the funding as a response to capacity constraints in UK primary care.
“When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity,” Dr Thuria Wenbar said. “What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing.”
She added that the company is “making healthcare as accessible as online banking,” and that the new funding is intended to help validate the model at scale.
Investor view: embedded health follows embedded finance
Christoph Ruedig, Partner at AlbionVC, will join Evaro’s board as part of the investment. He described the company as a category-defining player in what he called the “embedded health revolution.”
“We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution,” Ruedig said. “Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS.”
Regulated credentials and a multi-market strategy
Founded in 2018 by emergency physician Dr Thuria Wenbar and pharmacist researcher Dr Oskar Wenbar, Evaro said it serves three markets: consumer brands seeking new revenue opportunities, healthcare providers expanding digital capacity for common conditions, and employers deploying health benefits.
The company enables brands to offer prescription medication and related clinical services to their customers via embedded journeys. It said it has served more than 2 million patients and is among a small group of online pharmacy providers holding Care Quality Commission, General Pharmaceutical Council, and NHS licenses simultaneously—an important differentiator in a sector where regulatory compliance and clinical governance remain central to scaling.
Context: longer waits and rising interest in asynchronous care
The funding comes amid persistent pressure on UK primary care. Evaro cited figures indicating that 20.5 million people experienced month-long waits for a GP appointment in 2024, representing a 60% increase over seven years.
The company’s approach relies heavily on asynchronous consultations—digital interactions that do not require a live appointment—paired with remote diagnostics, prescribing, dispensing, and aftercare. A 2023 study in BJGP Open found that well-designed asynchronous consultations can resolve up to 66% of primary care cases without live appointments, highlighting the potential for such models to reduce demand for in-person capacity when deployed appropriately and safely.
Dr Oskar Wenbar, Chief Medical Officer and co-founder, said patient expectations have shifted toward convenience and speed. “Patients now expect the same convenience from healthcare that they get from banking or shopping – instant, mobile, on their terms,” he said, arguing that legacy processes still require phone calls, appointments, and physical visits even for minor conditions.
Part of a broader European HealthTech funding trend
Evaro’s raise arrives amid steady European investment in regulated, platform-driven digital healthcare and adjacent diagnostics. Recent funding cited in the wider HealthTech landscape includes Spain’s Tucuvi raising €17 million for voice-AI patient follow-up, and UK-based GlycanAge securing €7.4 million to advance glycan-based ageing diagnostics—an area aligned with Evaro’s stated interest in longevity medicine.
Other deals pointing to similar themes include Norway’s Noteless, which raised €3.5 million for AI documentation aimed at reducing clinician workload, Copenhagen’s Teton.ai closing a €17 million Series A for predictive intelligence in hospital care, and Poland’s Holi adding €3 million to expand a digital obesity treatment platform. Together, these rounds underscore a broader push toward scalable digital infrastructure designed to relieve strain on health systems.
Next steps: growth targets and expanded clinical scope
Evaro said it plans to reach 10 million patients over the next three years and to establish “healthcare-as-a-service” as a distinct category in the UK market. With new funding earmarked for expanded treatment areas, diagnostics, aftercare, and an API-first platform, the company is betting that regulated embedded care can move from early partnerships into a mainstream distribution channel for common conditions—while maintaining the clinical governance required for safe prescribing at scale.
Related
